ReviewWorld journal of gastroenterology2021
Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics.
Review in World journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 23 citations in OpenAlex.
- Association of skin microbiome with interleukin-23 in patients with plaque psoriasis.Postepy dermatologii i alergologii · 2025Article
- A practical approach to positioning therapies in ulcerative colitis.Journal of the Canadian Association of Gastroenterology · 2025Article
- Infection Risk and Vaccination in the Management of Psoriasis: Considerations for Biologic Therapy.Psoriasis (Auckland, N.Z.) · 2025Review
- Article
- Upadacitinib-Induced Hepatitis B Reactivation Leading to Liver Transplant.ACG case reports journal · 2024Article
- The Saudi consensus recommendations for the management of psoriatic arthritis (2023).Clinical rheumatology · 2024Review
- Hepatitis B Virus Reactivation with Immunosuppression: A Hidden Threat?Journal of clinical medicine · 2024Review
- Hepatotoxicity Induced by Biological Agents: Clinical Features and Current Controversies.Journal of clinical and translational hepatology · 2022Review
- Psoriatic Arthritis: The Influence of Co-morbidities on Drug Choice.Rheumatology and therapy · 2022Review
- Hepatitis B Virus Reactivation and Mycobacterial Infections Associated With Ustekinumab: A Retrospective Study of an International Pharmacovigilance Database.Frontiers in pharmacology · 2022Article
- Infections in the era of immunobiologicals.Anais brasileiros de dermatologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Hepatitis B virus reactivation (HBVr) can occur in patients treated with immunosuppressive medications. Risk stratification for HBVr based on hepatitis B virus (HBV) serology and viral load is an important strategy to determine appropriate HBV monitoring and antiviral prophylaxis use. Recent advances in the understanding of pathophysiology of autoimmune diseases have led the development of cytokine-targeted therapies. Tumor necrosis factor (TNF)-α inhibitors have been widely used for patients with inflammatory bowel disease, psoriasis, and rheumatic diseases. Further, the clinical benefits of interleukin (IL)-12/23, IL-17, or Janus kinases inhibitors have been demonstrated in these patients. It is well known that TNF-α inhibitor use can lead to HBVr, however, the risk of HBVr in patients undergoing non-TNF-targeted biologics have not been fully understood. In this review, we discuss the risk of HBVr in patients treated with non-TNF-targeted biologics, and immunological mechanisms of these medications causing HBVr.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.